Screenpoint Medical
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | 2.5m | 3.5m | 4.4m | 7.8m | 8.1m |
% growth | - | 40 % | 26 % | 76 % | 5 % |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | Spinout | ||
€500k | Grant | ||
€4.3m | Series B | ||
$28.0m | Series C | ||
Total Funding | $33.3m |
Recent News about Screenpoint Medical
EditScreenPoint Medical specializes in developing advanced AI-driven image analysis technology designed to automate the reading of mammograms and digital breast tomosynthesis (DBT) examinations. The company's flagship product, Transpara, is a decision support solution that aids radiologists and healthcare providers in early breast cancer detection and diagnosis. ScreenPoint Medical operates in the healthcare and medical imaging market, targeting radiologists, diagnostic centers, and healthcare providers. The business model is based on selling and licensing its AI software to medical institutions, generating revenue through software sales, subscriptions, and strategic partnerships. The company leverages Big Data, Deep Learning, and Artificial Intelligence to enhance the accuracy and efficiency of breast cancer screening, aiming to improve patient outcomes and reduce radiologist workload.
Keywords: AI, mammography, breast cancer, radiology, image analysis, healthcare, Deep Learning, Big Data, diagnostic centers, Transpara.